| trial | Stage | No. of patients | arms | Lymphadenectomy | RFS (%) | OS (%) | Hazard ratio for OS (RFS if no OS) (95% CI) |
| MAGIC [20] | cStage II-IVa | 250 | I: Preoperative ECF | D1/D2 | - | **36 | 0.75 (0.60 - 0.93 P = 0.009) |
| 253 | C: Surgery alone | - | **23 | ||||
| FNCLCC/ FFCD [21] | cStage M0 | 113 | I: Preoperative cisplatin + fluorouracil | D1/D2 | **34 | **38 | 0.69 (0.50 - 0.95 P = 0.02) |
| 111 | C: Surgery alone | **19 | **24 | ||||
| FLOT4 [23] | cStage I-IVA | 356 | I:Preoperative FLOT | D2 | ***30 | ***50 | 0.77 (0.63 - 0.94) |
| 360 | C: Preoperative ECF/ECX | ***18 | ***35 | ||||
| PRODIGY [29] | cStage II-IVA | 266 | I1: DOS + Surgery + S-1 | D2 | *66.3 | *74.2 | 0.84 (0.60 - 1.19 P = 0.338) |
| 264 | I2: Surgery + S-1 | *60.2 | *73.4 | ||||
| RESOLVE [18] | cStage III-IVM0 | 345 | C: Surgery + CapOx | D2 | *51.1 | - | - |
| 340 | I1: Surgery + SOX | *56.5 | - | 0.86 (0.68 - 1.07 P = 0.17) | |||
| 337 | I2: Preoperative SOX | *59.4 | - | 0.77 (0.61 - 0.97 P = 0.028) |